(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 November 2017 (16.11.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/194912 A1

(51) International Patent Classification:
A61K 48/00 (2006.01) *C07K 14/47* (2006.01)

(21) International Application Number:
PCT/GB2017/051233

(22) International Filing Date:
03 May 2017 (03.05.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1608046.7 09 May 2016 (09.05.2016) GB

(71) Applicants: **CAMBRIDGE ENTERPRISE LIMITED** [GB/GB]; The Old Schools, Trinity Lane, Cambridge Cambridgeshire CB2 1TN (GB). **THE SYDNEY CHILDREN'S HOSPITALS NETWORK (RANDWICK AND WESTMEAD)** [AU/AU]; (incorporating The Royal Alexandra Hospital For Children), Cnr Hawkesbury Road and Hainsworth Street, Westmead, New South Wales (AU).

(72) Inventors: **LACHMANN, Peter**; Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge Cambridgeshire CB3 0ES (GB). **ALEXANDER, Ian**; Children's Medical Research Institute, 214 Hawkesbury Road, Westmead, Sydney, New South Wales 2145 (AU).

(74) Agent: **O'BRIEN Simon**; D Young & Co LLP, 120 Holborn, London, EC1N 2DY (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2017/194912 A1

(54) Title: TREATMENT OF COMPLEMENT-MEDIATED DISORDERS

(57) Abstract: Methods of treatment of complement-mediated disorders, in particular disorders associated with over-activity of the complement C3b feedback cycle (for example, age-related macular degeneration (AMD)), using gene therapy is described. According to the methods, levels of complement Factor I are elevated by administration of a recombinant viral vector encoding Factor I such that a therapeutically effective amount of the encoded Factor I is expressed from the vector in the subject. Recombinant viral vectors encoding Factor I, recombinant virus particles encapsidating the vectors, and their use in the methods of treatment, is also described.